Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Goldenwell BiotechGWLL 30 Debt-to-Equity is -0.27 as of Mar. 2026. GuruFocus rates GWLL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,745 Consumer Packaged Goods companies, Goldenwell Biotech ranks worse than 57306.53% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Goldenwell Biotech's Debt-to-Equity or its related term are showing as below:
GWLL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.04 Med: 0.12 Max: 1.14
Current: -0.27
During the past 6 years, the highest Debt-to-Equity Ratio of Goldenwell Biotech was 1.14. The lowest was -2.04. And the median was 0.12.
GWLL's Debt-to-Equity is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 0.41
vs GWLL: -0.27
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Goldenwell Biotech Debt-to-Equity Related Terms
Goldenwell Biotech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Goldenwell Biotech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GWLL vs LFVN, FTLF, CLNN: Debt-to-Equity Comparison
For the Packaged Foods subindustry, Goldenwell Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Goldenwell Biotech Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Goldenwell Biotech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Goldenwell Biotech (GWLL) has a Debt-to-Equity of -0.27 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Goldenwell Biotech and its competitors. According to the industry distribution chart, Goldenwell Biotech ranks #999999 out of 1745 companies in the Consumer Packaged Goods industry.
Is Goldenwell Biotech's Debt-to-Equity too high?
Goldenwell Biotech's current Debt-to-Equity is -0.27. Based on the distribution chart, Goldenwell Biotech ranks #999999 out of 1745 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Goldenwell Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Goldenwell Biotech's Debt-to-Equity compare to LFVN and FTLF?
According to the Consumer Packaged Goods industry distribution chart, Goldenwell Biotech ranks #999999 out of 1745 companies for Debt-to-Equity. This places Goldenwell Biotech in the lower half of its industry. The industry median Debt-to-Equity is 0.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,745 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Goldenwell Biotech and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Goldenwell Biotech's current Debt-to-Equity is -0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Goldenwell Biotech stock overvalued right now?
Goldenwell Biotech (GWLL) has a current Debt-to-Equity of -0.27. The current Debt-to-Equity is -0.27. Goldenwell Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Goldenwell Biotech (GWLL), the current Debt-to-Equity is -0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Goldenwell Biotech Inc is engaged in the research and development, production, and sales of healthcare and supplement products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
30GF Score
Get the complete analysis for GWLL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GWLL has been successfully added to your 
